Ledipasvir/Sofosbuvir plus Ribavirin (LDV/SOF+RBV) for 12 Weeks in Decompensated HCV Genotype 1 Patients: SOLAR-1 and-2 Studies Compared to a Real-World Dataset

被引：0
|
作者：
Charlton, Michael R. [1 ]
Cheung, Michelle C. [2 ]
Manns, Michael P. [3 ,4 ]
Sajed, Nika [5 ]
Troke, Philip [6 ]
Spellman, James G. [5 ]
Copans, Amanda [5 ]
Arterburn, Sarah [5 ]
Brainard, Diana M. [5 ]
Irving, William [7 ]
Foster, Graham R. [2 ]
机构：
[1] Intermt Med Ctr, Div Hepatol & Liver Transplantat, Salt Lake City, UT USA
[2] Queen Mary Univ London, Blizard Inst, Liver Unit, London, England
[3] Hannover Med Sch, Gastroenterol Hepatol & Endocrinol, Hannover, Germany
[4] German Ctr Infect Res DZIF, Hannover, Germany
[5] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA
[6] Gilead Sci Ltd, London, England
[7] NIHR Nottingham Digest Dis Biomed Res Unit, Nottingham, England
来源：
HEPATOLOGY | 2016年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
966
引用
收藏
页码：489A / 490A
页数：2
相关论文
共 50 条
  • [21] Utilization of DAA therapies ledipasvir/sofosbuvir and sofosbuvir/velpatasvir in patients with genotype 1 HCV: real-world experience from the TRIO Network
    Tsai, N.
    Bacon, B.
    Curry, M.
    Dieterich, D.
    Flamm, S.
    Kowdley, K.
    Milligan, S.
    Younossi, Z.
    Afdhal, N.
    [J]. JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S726 - S726
  • [22] Real-World Experiences with the Combination Treatment of Ledipasvir plus Sofosbuvir for 12 Weeks in HCV Genotype 1-Infected Japanese Patients: Achievement of a Sustained Virological Response in Previous Users of Peginterferon plus Ribavirin with HCV NS3/4A Inhibitors
    Kanda, Tatsuo
    Yasui, Shin
    Nakamura, Masato
    Suzuki, Eiichiro
    Arai, Makoto
    Ooka, Yoshihiko
    Ogasawara, Sadahisa
    Chiba, Tetsuhiro
    Saito, Tomoko
    Haga, Yuki
    Takahashi, Koji
    Sasaki, Reina
    Wu, Shuang
    Nakamoto, Shingo
    Tawada, Akinobu
    Maruyama, Hitoshi
    Imazeki, Fumio
    Kato, Naoya
    Yokosuka, Osamu
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (05)
  • [23] REAL-WORD EFFECTIVENESS OF 8, 12 AND 24 WEEKS LEDIPASVIR (LDV)/SOFOSBUVIR (SOF)-BASED THERAPY FOR HEPATITIS C VIRUS (HCV) GENOTYPE 1: ANALYSIS IN A LARGE INTEGRATED HEALTH CARE SYSTEM
    Lai, J.
    Witt, M.
    Witt, D.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 64 : S778 - S778
  • [24] Real-world effectiveness and safety of sofosbuvir and ledipasvir with or without ribavirin for patients with hepatitis C virus genotype 1 infection in Taiwan
    Liu, Chen-Hua
    Liu, Chun-Jen
    Su, Tung-Hung
    Yang, Hung-Chih
    Hong, Chun-Ming
    Tseng, Tai-Chung
    Chen, Pei-Jer
    Chen, Ding-Shinn
    Kao, Jia-Horng
    [J]. PLOS ONE, 2018, 13 (12):
  • [25] SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAIVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY
    Kowdley, K. V.
    Stuart, G. C.
    Reddy, R. K.
    Rossaro, L.
    Bernstein, D. E.
    An, D.
    Svarovskaia, E. S.
    Hyland, R. H.
    Pang, P. S.
    Symonds, W. T.
    Mchutchison, J. G.
    Muir, A. J.
    Pockros, P. J.
    Pound, D.
    Fried, M. W.
    [J]. JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S23 - S24
  • [26] Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study
    Kowdley, Kris V.
    Gordon, Stuart C.
    Reddy, K. Rajender
    Rossaro, Lorenzo
    Bernstein, David
    An, Di
    Svarovskaia, Evguenia
    Hyland, Rob H.
    Pang, Phil
    Symonds, William T.
    McHutchison, John G.
    Muir, Andrew J.
    Pockros, Paul J.
    Pound, David
    Fried, Michael W.
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S926 - S926
  • [27] Effectiveness of 8-or 12-weeks of ledipasvir and sofosbuvir in real-world treatment-naive, genotype 1 hepatitis C infected patients
    Curry, M. P.
    Tapper, E. B.
    Bacon, B.
    Dieterich, D.
    Flamm, S. L.
    Guest, L.
    Kowdley, K. V.
    Lee, Y.
    Milligan, S.
    Tsai, N.
    Younossi, Z.
    Afdhal, N. H.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (05) : 540 - 548
  • [28] Eight weeks treatment duration with Ledipasvir/Sofosbuvir (LDV/SOF) is effective for appropriately selected patients with genotype 1 Hepatitis C virus (HCV) infection: an analysis of multiple real world cohorts totaling >6,500 patients
    Sundaram, Vinay
    Jeon, Christie
    Qureshi, Kamran
    Latt, Nyan L.
    Sahota, Amandeep K.
    Curry, Michael P.
    Tsai, Naoky C.
    Chaiyakunapruk, Nathorn
    Lee, Yoori
    Lott, Stephen
    Petersen, Joerg
    Buggisch, Peter
    Kowdley, Kris V.
    [J]. HEPATOLOGY, 2016, 64 (06) : 1129A - 1129A
  • [29] Real-world Effectiveness (RWE) of Sofosbuvir plus Ribavirin (SOF plus RBV) Chronic Hepatitis C Genotype 2 (CHC GT 2) in Asia: A Systemic Review and Meta-analysis of Pooled SVR12
    Wei, Bin
    Ji, Fanpu
    Yeo, Yee Hui
    Zou, Biyao
    Ogawa, Eiichi
    Henry, Linda
    Cheung, Ramsey
    Li, Zongfang
    Dang, Shuangsuo
    Furusyo, Norihiro
    Nguyen, Mindie H.
    [J]. HEPATOLOGY, 2017, 66 : 811A - 811A
  • [30] Sofosbuvir Plus Ribavirin for 12 Weeks in Genotype 2 HCV Compensated Cirrhotic Patients; A Comparative Analysis of VALOR-HCV SVR Data to Registration Trials and Real World Cohorts
    Ho, Samuel B.
    Monto, Alexander
    Peyton, Adam
    Kaplan, David E.
    Byrne, Sean
    Moon, Scott
    Le, Hadley
    Copans, Amanda
    Rossaro, Lorenzo
    Zhu, Yanni
    Brainard, Diana
    Guyer, William
    Shaikh, Obaid
    Fuchs, Michael
    Morgan, Timothy R.
    [J]. GASTROENTEROLOGY, 2016, 150 (04) : S925 - S925
12345